Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to Pregabalin

Haisco Pharmaceutical Group

Status and phase: Enrolling; Phase 2

Conditions: Diabetic Peripheral Neuropathic Pain

Treatments: Drug: Pregabalin 150mg BID; Drug: HSK16149 20mg BID

Study type: Interventional

Funder types: Industry

Identifiers

NCT06490484

HSK16149-207

Details and patient eligibility

About

Investigate the efficacy and safety of HSK16149 capsule in Chinese patients with Diabetic Peripheral Neuropathic Pain (DPNP) who had an inadequate response to Pregabalin, following 4 weeks treatment in comparison to Pregabalin

Enrollment: 90 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Signed informed consent;
2. Males or females aged 18-75 years of age inclusive;
3. Diagnosis of diabetic peripheral neuropathic pain (DPNP) and diabetic peripheral neuropathy (DPN) pain ≥ 6 months;
4. HbA1c ≤ 11.0% at screening and on a stable anti-diabetic medication regimen for at least 30 days prior to screening;
5. Have a visual analog scale (VAS) pain value ≥60 mm in the past 24 h during screening;
6. DPNP patients are currently receiving continuous treatment with pregabalin for more than 4 weeks who had an inadequate response.

Exclusion criteria

1. Peripheral neuropathy or pain unrelated to DPN that may confuse the assessment of DPNP.

2. Skin conditions in the area affected by neurupathy that could alter sensation.

3. Chronic systemic diseases that may affect subjects' participation in the study.

4. Severe hematologic, hepatic or renal dysfunction, the subject will be excluded if:

   1. Neutrophils < 1.5 × 10^9/L, or platelet < 90 × 10^9/L, or hemoglobin < 100 g/L;
   2. AST/ALT > 2.5 × upper limit of normal (ULN), or TBIL > 1.5 × ULN;
   3. Estimation of glomerular filtration rate (eGFR) < 60 mL/min / 1.73 m^2;
   4. Creatine kinase > 2.0 × ULN.

5. History of substance abuse or alcohol abuse.

6. Acute complications of diabetes in the 6 months prior to screening.

7. Any active infections at screening.

8. HBsAg or HCV Ab positive, or HIV Ab positive, or serum TP Ab positive.

9. Inability or unwillingness to discontinue any other prohibited concomitant medications.

10. History of allergic or medically significant adverse reaction to investigational products or their excipients, duloxetine or related compounds.

11. History of suicidal behavior or attempted suicide.

12. Pregnant or preparing for pregnancy or breastfeeding during the study period, or subjects were not willing to use reliable contraceptives methods from the date of ICF signature until 28 days after the last trial drug administration, or planning to use progesterone contraceptives during this period.

13. Participated in another clinical study within 30 days prior to screening.

14. Other conditions of the subjects who are unlikely to comply with the protocol.

15. The investigators determine that there are other conditions that are not suitable for participation in this study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

90 participants in 2 patient groups

HSK16149 20mg BID

Experimental group

Description:

Drug: HSK16149 20mg BID HSK16149 20mg, orally twice a day; treatment period: 4 weeks fixed dose.

Treatment:

Drug: HSK16149 20mg BID

Pregabalin 150 BID

Experimental group

Description:

Drug: Pregabalin 150mg BID Pregabalin 150mg, orally twice a day; treatment period: 1 week titration and 3 weeks fixed dose.

Treatment:

Drug: Pregabalin 150mg BID